StemGenex CSO Tells FDA at Hearing to Regulate Adult Stem Cell Therapies as ‘Blood Tissue Product’ – Multiple Sclerosis News Today
Multiple Sclerosis News Today |
StemGenex CSO Tells FDA at Hearing to Regulate Adult Stem Cell Therapies as 'Blood Tissue Product'
Multiple Sclerosis News Today In a presentation at a U.S. Food and Drug Administration (FDA) public hearing earlier this month, the chief scientific officer of StemGenex Medical Group, Steven A. Brody, MD, PhD, said succinctly: “Stem cells have arrived and have captivated the … Cancer Stem Cell (CSC) Therapy Market Research Report Now Available at Research Corridor |
